Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
Ma J, Lin Z, Zhang Y, Ding Y, Tang Q, Qian Y, Jin B, Luo RY, Liao WL, Thyparambil S, Han Z, Chou CJ, Schilling J, Li Q, Zhang M, Lin Y, Ma Y, Sylvester KG, Nagpal S, McElhinney DB, Ling XB, Chen B.
Ma J, et al. Among authors: luo ry.
Front Immunol. 2024 Aug 1;15:1343109. doi: 10.3389/fimmu.2024.1343109. eCollection 2024.
Front Immunol. 2024.
PMID: 39144147
Free PMC article.